A Randomised, Double-Blind, Placebo-Controlled Trial with Vitamin D3 in MS: Subgroup Analysis of Patients with Baseline Disease Activity Despite Interferon Treatment

Table 2

MRI results in the vitamin D-and placebo-treated active subgroup patients.

			Vitamin D		Placebo	𝑃 value
T2 BOD (mm^3),; median (SE)	Baseline	𝑛=15	4391 (2305)	𝑛=15	9930 (2375)	0.105
	Change from baseline	𝑛=13	104 (240)	𝑛=14	570 (3259)
Number of T1-enhancing lesions,; mean (SD)	Baseline	𝑛=15	1.5 (3.6)	𝑛=15	1.5 (2.9)
	Month 12	𝑛=13	0.1 (0.3)	𝑛=14	1.5 (5.0)	0.027^*
Patients with T1-enhancing lesions (𝑛,%)	Baseline	𝑛=15	6 (40%)	𝑛=15	6 (40%)
	Month 12	𝑛=13	1 (8%)	𝑛=14	3 (21%)
Number of new or enlarging T2/PD lesions, median (SD)	Month 12	𝑛=13	0.61 (1.26)	𝑛=14	1.85 (2.44)	0.132
Patients with new or enlarging lesions on T2/PD, mean (SD)	Month 12	𝑛=13	3 (23%)	𝑛=13	8 (57%)	NS
MRI activity (𝑛,%)	Baseline	𝑛=15	6 (40%)	𝑛=15	6 (40%)	0.080
	Month 12	𝑛=13	3 (23%)	𝑛=14	8 (57%)

BOD: burden of disease; MRI activity: Gadolinium-enhancing T1 lesions or new/enlarging T2 lesions; 𝑛: number of patients. ^*Indicates statistically significant. NS: not significant.